

Let Curves Speak: A Continuous Glucose Monitor based Large Sensor Foundation Model for Diabetes Management

Junjie Luo, M.S.,^{1,2} Abhimanyu Kumbara, M.S.,³ Mansur Shomali, M.D.,³ Rui Han, M.S.,² Anand Iyer, Ph.D., M.B.A.,³ Ritu Agarwal, Ph.D., M.B.A.,² Gordon Gao, Ph.D., M.B.A.,^{2*}

Author affiliations

¹ School of Medicine, Johns Hopkins University

² The Center for Digital Health and Artificial Intelligence, Carey Business School, Johns Hopkins University

³ WellDoc Inc.

* Corresponding author: Prof. Gordon Gao, Carey Business School of Johns Hopkins University, co-director of the Center for Digital Health and AI (CDHAI), Email: gordon.gao@jhu.edu, ORCID: 0000-0002-2336-9682

Abstract

Background: While previous studies of artificial intelligence (AI) in diabetes management focus on long-term risk, research on near-future glucose prediction remains limited but important as it enables timely diabetes self-management. Integrating AI with continuous glucose monitoring (CGM) holds promise for enhancing near-future glucose prediction. However, existing models have limitations in capturing complex patterns of blood glucose fluctuations and demonstrate poor generalizability across patients. A robust approach is needed to leverage massive CGM data for near-future glucose prediction.

Methods: We propose large sensor models (LSMs) to capture latent knowledge in CGM data by modeling patients as sequences of glucose. CGM-LSM is pretrained on 15.96 million glucose records from 592 diabetes patients for near-future glucose prediction. We evaluated CGM-LSM against state-of-the-art methods using the OhioT1DM dataset across various metrics, prediction horizons, and unseen patients. Additionally, we assessed its generalizability and performance variations across patient-specific factors like diabetes type, age, gender, and hour of day.

Results: CGM-LSM achieved exceptional performance, with an rMSE of 29.81 mg/dL for type 1 diabetes (T1D) patients and 23.49 mg/dL for type 2 diabetes (T2D) patients in a two-hour prediction horizon. For the OhioT1DM dataset, CGM-LSM achieved a one-hour rMSE of 15.64 mg/dL, halving the previous best of 31.97 mg/dL without training on this dataset. Robustness analyses revealed consistent performance not only for unseen patients and future periods, but also across diabetes type, age, and gender. The model also demonstrated adaptability to different hours of day, maintaining accuracy across periods of various activity intensity levels.

Conclusions: CGM-LSM represents a transformative step in diabetes management by leveraging pretraining to uncover latent glucose generation patterns in sensor data. This approach significantly improves prediction accuracy, robustness, and generalizability, providing timely and personalized insights to support self-management. Our findings also underscore the broader potential of LSMs to drive innovation across domains involving complex sensor data.

Introduction

Diabetes imposes significant burdens on individuals, families, and healthcare providers. Uncontrolled diabetes has been associated with a variety of severe medical complications, including heart attacks¹, kidney failure², and diabetic neuropathy³. In 2021, 38.4 million Americans (11.6% of the U.S. population) had diabetes, making it the eighth leading cause of death⁴. By 2022, diabetes management costs had soared to approximately \$412.9 billion annually (25% of total healthcare expenditures)⁴. The rising societal and economic burden of diabetes combined with a growing global shortage of healthcare professionals necessitates new approaches to diabetes care and prevention⁵.

Effective self-management is crucial for people with diabetes to manage their condition and avoid complications. To inform their daily decision-making processes, patients need actionable information. Artificial intelligence (AI) holds considerable promise to provide such information by generating personalized interventions tailored to individual needs. However, most AI applications in diabetes management have been centered on predicting the overall risk of diabetes progression over long time horizons, and such predictions are difficult for individuals to convert into daily diabetes management activities. This shortcoming underscores the need for diabetes management AI solutions that can provide timely, micro-level, personalized, actionable predictions to enable patients to improve their self-care⁶⁻⁸.

In recent years, continuous glucose monitoring (CGM) systems, which continuously measure glucose values every five minutes, have emerged as a critical tool in diabetes control. One particularly promising approach to meeting the patient needs described above lies in combining CGM with AI to predict near-future glucose values⁹. However, little research has addressed this task, which is inherently challenging due to the complexity and variability of individual behaviors captured by CGM. This makes it difficult to accurately predict a patient’s glucose levels for the next two hours¹⁰. Studies using simulated CGM data or datasets from a limited number of patients report poor prediction performance¹¹⁻¹⁶. Such poor performance can be caused not only by inadequate data but also by training the model using random initialization with zero glucose generation knowledge. In this context, the question of how to utilize the hidden knowledge within CGM data patterns to empower prediction models remains unaddressed.

To address this gap, we present a new approach to glucose prediction for diabetes management that harnesses the pretraining technique exemplified in large language models (LLMs). We pretrain the model to learn the latent glucose generation mechanisms hidden in massive CGM data. Considering that language is represented as a sequence of tokens and LLMs learn through next-token prediction, we also model person-generated glucose data as a sequence of time steps (e.g., every five minutes) and propose a large sensor model (LSM) to learn massive sensor data with next-step prediction. We hypothesize that an LSM pretrained on CGM data (CGM-LSM) can learn hidden glucose generation patterns and achieve high performance in predicting glucose values.

We develop the CGM-LSM on a large CGM dataset with 15.96 million glucose records from 592 diabetes patients. We first validate its efficiency for improving near-future glucose prediction on metrics of accuracy, robustness, and prediction horizon flexibility. Our model demonstrates dramatically superior performance. Benchmarked against the public OhioT1DM dataset, CGM-

LSM achieved a root Mean Squared Error (rMSE) of 15.64 mg/dL, which is nearly half that of the best existing approaches, even though our model was not trained on the OhioT1DM dataset¹⁴.

A series of analyses assess the model’s generalizability, including prediction horizons, performance metrics, diabetes types, unseen patients, and age and gender groups. In addition, we examine how model performance changes based on the specific hours of the day during which predictions are made. The model exhibits strong and robust predictive performance for these dimensions. This study first proposes the LSM pretrained with sensor data and demonstrates its significant improvement in near-future glucose prediction. It offers a new methodology not only for timely and personalized diabetes self-management but also for learning from massive sensor data.

Methods

1. Datasets

The key data point in our study is an “instance,” defined as a combination of a patient and an observation datetime. This datetime represents the time when the model is triggered to observe the patient’s records and generate predictions. As shown in Figure. 1b, inclusion as a valid instance requires 288 CGM entries from the 24 hours prior to the datetime and 24 entries in the subsequent 2 hours, for a total of 26 hours of CGM data.

	Records (Patients)	Type 1 Diabetes (T1D)						Type 2 Diabetes (T2D)					
		Complete Dataset	Dataset	Training	Internal	Temporal	Hold-Out	Complete Dataset	Dataset	Training	Internal	Temporal	Hold-Out
Patients	15,961,183 (592)	7,788,836 (291)	779,111 (290)	560,184 (257)	61,979 (256)	68,762 (257)	88,186 (33)	8,172,347 (301)	817,125 (301)	597,975 (274)	66,257 (273)	73,293 (273)	79,600 (27)
Age Group													
18-39 years old	3,425,955 (129)	2,901,601 (109)	290,615 (108)	209,054 (94)	23,321 (94)	25,837 (94)	32,403 (14)	524,354 (20)	52,077 (20)	39,252 (19)	4,440 (19)	4908 (19)	3,477 (1)
40-64 years old	8,040,123 (299)	3,249,786 (123)	324,649 (123)	231,576 (108)	25,408 (107)	28,412 (108)	39,253 (15)	4,790,337 (176)	478,441 (176)	347,663 (158)	38,481 (158)	42,483 (158)	49,814 (18)
65+ years old	4,495,105 (164)	1,637,449 (59)	163,847 (59)	119,554 (55)	13,250 (55)	14,513 (55)	16,530 (4)	2,857,656 (105)	286,607 (105)	211,060 (97)	23,336 (96)	25,902 (96)	26,309 (8)
Gender Group													
Female	7,133,594 (283)	4,150,047 (165)	415,869 (164)	295,753 (144)	32,910 (144)	36,478 (144)	50,728 (20)	2,983,547 (118)	297,557 (118)	224,985 (109)	24,768 (108)	27,582 (108)	20,222 (9)
Male	8,827,589 (309)	3,638,789 (126)	363,242 (126)	264,431 (113)	29,069 (112)	32,284 (113)	37,458 (13)	5,188,800 (183)	519,568 (183)	372,990 (165)	41,489 (165)	45,711 (165)	59,378 (18)

Table 1. Data description for the WellDoc dataset, showing the number of instances and patient counts across subsets by diabetes type (Type 1 Diabetes [T1D] and Type 2 Diabetes [T2D]), age groups, and gender. Subsets include the complete dataset, training, internal, temporal, and hold-out sets.


To pretrain our CGM-LSM model we built the WellDoc dataset, which contains 592 individuals diagnosed with diabetes (291 T1D and 301T2D). T1D (type 1 diabetes) is more prevalent than T2D (type 2 diabetes) in the younger demographic of 18-39 years (109 individuals with T1D; 20

with T2D). The final dataset contains 15,961,183 valid instances, 7,788,836 from T1D patients and 8,172,347 from T2D. The distribution is consistent across various demographics, with 2,901,601 instances involving T1D individuals aged 18-39 and 524,354 involving their T2D counterparts. Female T1D patients account for 4,150,047 instances, while T2D females contribute 2,983,547 instances.


In addition to this unique dataset, we applied our model to the OhioT1DM dataset¹⁷ to compare it with previous research. This dataset includes 4 T1D patients with a total 5,802 valid instances.

2. CGM-LSM Pretraining and Generation


a. Model Development and Evaluation Dataset Construction



b. Instance Construction with Before 24H CGM and After 2H CGM



c. Pre-training Process



d. Prediction/Generation Process




Figure 1. **The workflow of dataset construction and CGM-LSM development.** **A.** The instances selection process to construct internal test set, temporal test set, hold-out-test set, and training set. **B.** For one instance, the input-output pair construction process. Each instance is a combination of a patient and an instance datetime. The instance contains 288 CGM records before 24 hours and 24 CGM records after 2 hours. **C.** The pretraining process for one instance given 26-hour CGM records. **D.** The prediction (generation) process for one instance with 24-hour CGM records.

As shown in Figure. 1a, to test the model’s robustness and generalizability, we randomly split the dataset into two patient groups: hold-in and hold-out. Data from hold-out patients (10% of patients) were excluded from the training phase and reserved exclusively as the “hold-out” test set. Each

“hold-in” patient’s instances were chronologically sorted based on observation datetimes. The latter 10% were reserved to form the “temporal” test set, intended for evaluating model performance on unseen future periods. The remaining 90% of instances were further randomly split, with 10% used as the “internal” test set and 80% as the “training” dataset. This stratification allowed the model to be evaluated on unseen future periods and on unseen patients. To mitigate overfitting and enhance computational efficiency, a random 10% down-sampling was applied to each dataset. The final numbers of patients and instances are summarized in Table 1.

The training process (Fig. 1c) employed transformer-decoder architecture¹⁸ to develop CGM-LSM by conducting autoregression tasks. For each instance from the training set, the model predicts the glucose value in the next time step by going through each time step over the 26-hour period.

In the generation process (Fig. 1d) for each instance, the model takes the previous 24 hours of CGM data as input to predict the glucose values for the subsequent two hours. The performance of these predictions was evaluated by comparing the root mean square error (rMSE) between the predicted and actual glucose values for the next half hour, one hour, and two hours respectively. Details of the model training and inference are in the appendix section.

Results

1. CGM-LSM Performance for Near Future Glucose Predictions

Model	Dataset		rMSE-30min mg/dL	rMSE-1H mg/dL	rMSE-2H mg/dL
Baseline	OhioT1DM		18.64 (2.60)	31.97 (3.62)	-
CGMLSM	OhioT1DM		9.358 (0.684)	15.64 (1.078)	26.296 (1.664)
	WellDoc T1D	Internal Test	8.403 (0.066)	16.049 (0.118)	28.277 (0.188)
		Temporal Test	9.155 (0.068)	17.013 (0.118)	29.426 (0.184)
		Hold-Out Test	8.926 (0.056)	16.905 (0.101)	29.812 (0.16)
	WellDoc T2D	Internal Test	7.441 (0.055)	13.418 (0.094)	22.649 (0.147)
		Temporal Test	8.025 (0.058)	14.073 (0.095)	23.216 (0.143)
Hold-Out Test		7.772 (0.055)	13.877 (0.091)	23.494 (0.143)	

Table 2: Comparative performance of predictive models for future glucose levels, using Root Mean Square Errors (rMSE). Each entry displays the mean rMSE followed by the confidence interval width in parentheses, indicating the range within which the true mean is expected to lie with 95% confidence.

As reported in Table 2, CGM-LSM significantly outperformed baseline models on the OhioT1DM data, despite not being trained on it. At a 30-minute prediction horizon, rMSE dropped from 18.64mg/dL to 9.36mg/dL, and at one hour, from 31.97mg/dL to 15.64mg/dL—nearly a 50% reduction. These results underscore the effectiveness of our pretraining approach for modeling glucose generation from large-scale CGM data. Strong performance on unseen patients indicates that the model avoided overfitting and captured generalizable glucose generation patterns.

Our analysis introduced new results for two-hour (2H) prediction performance in diabetes management, a previously unstudied time horizon. The model achieved an rMSE of 26.30mg/dL for 2H predictions on the OhioT1DM dataset, outperforming the baseline's one-hour (1H) rMSE of 31.97mg/dL. This demonstrates CGM-LSM's ability to handle extended prediction horizons with high accuracy despite increased forecasting challenges. Additional metrics for model evaluation, MAE, MAE(10), and region accuracy are reported in the appendix. The results consistently show CGM-LSM's high accuracy across metrics and test scenarios, highlighting its robustness and resistance to overfitting.

2. CGM-LSM Performance for an Unseen Future and Unseen Patients

Assessing the model's ability to generalize to real-world scenarios, such as future periods and unseen patients, is crucial for practical disease management. We hypothesized that temporal and hold-out datasets would pose greater challenges for CGM-LSM than the internal test set. These challenges arise from temporal shifts in the future set and unseen patients in the hold-out set, which deviate from the training data distribution.

As a result, despite the increased complexity, CGM-LSM's performance gap between the temporal and hold-out sets versus the internal set remained minimal. For T1D-2H predictions, rMSE was 28.28mg/dL for the internal set, increasing slightly to 29.43mg/dL (+4.07%) for the temporal subset and 29.81mg/dL (+5.41%) for the hold-out set. Similarly, for T2D-2H predictions, rMSE increased modestly from 22.65mg/dL for the internal set to 23.22mg/dL (+2.52%) for the temporal subset and 23.49mg/dL (+3.71%) for the hold-out set. These results show that while temporal and hold-out predictions were indeed more challenging, CGM-LSM maintained high accuracy, demonstrating robustness to temporal shifts and patient variability.

3. Performance Across Diabetes Type, Age, and Gender

Diabetes is a complicated disease with distinctive glucose generation mechanisms among patients. A patient's diabetes type, age, and gender significantly influence how glucose levels evolve over time^{19,20}. Considering this heterogeneity, we analyzed CGM-LSM's performance across diabetes type, age, and gender.

CGM-LSM demonstrated strong performance for both T1D and T2D patients. For T1D patients, rMSE scores were 8.93mg/dL (30min), 16.91mg/dL (1H), and 29.81mg/dL (2H). Performance was better for T2D patients, with lower rMSE scores of 7.77mg/dL (30min), 13.88mg/dL (1H), and 23.49mg/dL (2H). These results underscore the model's robustness across diabetes types. For T2D, the rMSE rose slightly by 3.71% from 22.65mg/dL (internal) to 23.49mg/dL (hold-out), as shown in Table 2. For T1D, the rMSE increase was larger, rising by 5.41% from 28.28mg/dL (internal) to 29.81mg/dL (hold-out), which was both proportionally and absolutely higher. This indicates that CGM-LSM has higher generalizability for unseen T2D patients than T1D patients.

Figure 2.a shows rMSE-2H performance differences across age groups and evaluation sets. These results indicate stable CGM-LSM performance across age groups. In T1D hold-out sets, rMSE scores ranged from 24.77 to 31.78mg/dL, or 83.09% to 106.71% of the overall rMSE (29.81mg/dL). For T1D, rMSEs peaked in the 18-39 group, decreased in the 40-64 group, and

stabilized further in the 65+ cohort. The 65+ cohort also had the smallest gap between internal and hold-out sets. These findings suggest that our model provides greater accuracy and robustness for older groups, possibly due to differences in disease management or progression. For T2D, CGM-LSM showed a high error rate in the hold-out set for the 18-39 group. This spike likely reflects the small sample size, with only one T2D patient in the hold-out set (Table 1). Excluding this outlier, T2D rMSEs were lower and more uniform across age groups compared to T1D. This indicates greater accuracy and robustness for T2D.





Figure 2: **Model Performance in 2-Hour Glucose Prediction Across Age and Gender**

A. Model performance across age groups (18-39, 40-64, 65+), showing rMSE-2H values for Type 1 and Type 2 Diabetes prediction across different test sets. B. Model performance across gender, showing rMSE-2H values for Type 1 and Type 2 Diabetes prediction across different test sets.

Figure 2.b highlights CGM-LSM’s performance across gender, showing stable results across groups. For T1D hold-out sets, rMSE scores ranged from 27.00 to 31.88mg/dL (90.57%–106.94% of the overall 29.81mg/dL). Males consistently had better prediction performance than females across all evaluation sets for both T1D and T2D. Among T1D patients, the rMSE gap between internal and hold-out sets was notably larger for females (3.19mg/dL) than for males (-0.8mg/dL).

These findings suggest the need for tailored model improvements to better accommodate unseen female T1D patients.

5. Performance across Prediction Hour of the Day




Figure 3: **Performance over Prediction-Making Hours of the Day**
Model performance across 24 hours, showing rMSE-2H values for Type 1 and Type 2 Diabetes prediction across different test set.

Human glucose generation is influenced by lifestyle factors like diet, exercise, and medications. Glucose levels and fluctuations vary by time of day due to their association with human activities like eating and exercise. Given this link, understanding CGM-LSM’s performance at different hours is crucial for its safe application. Figure 4 shows CGM-LSM’s prediction performance at different hours of the day, measured via rMSE over 30-minute, one-hour, and two-hour horizons using the hold-out set for T1D and T2D patients.

Each line in Figure 3 represents the model’s rMSE values across different hours of the day. The model performed consistently well across prediction settings. Clear trends emerged based on prediction horizons and time of day. Shorter horizons (e.g., 30 minutes) had lower rMSE, reflecting better capture of short-term fluctuations. The rMSE score peaked at noon and evening hours. The higher rMSE during these hours likely reflects impacts from diet, exercise, and treatment routines. In contrast, rMSE was notably lower at night. Nocturnal glucose levels, which are less influenced by behavior, allowed CGM-LSM to predict more accurately. These findings demonstrate the importance of temporal factors and human behaviors in glucose prediction.

Discussion

Accurate near-future glucose prediction is critical for personalized and real-time diabetes management and is an intrinsically difficult task. In this study, we introduced the large sensor model for CGM to learn glucose generation mechanisms hidden in large CGM data. We

hypothesized that the LSM could learn effectively, yielding improvements over existing methods. With 15.96 million glucose records (~152 patient-years of CGM data) from 592 diverse patients, our CGM-LSM was effectively pretrained, and it achieved significant improvements in near-future glucose predictions. The model demonstrated its accuracy and robustness across various prediction horizons, patient types, unseen periods, and prediction contexts.

Using a one-hour horizon, our model achieved an rMSE that is 50% lower than existing methods for T1D patients, demonstrating high predictive accuracy. Previous studies have not explored the two-hour prediction horizon or prediction performance for type 2 diabetes, which is crucial for glucose monitoring. Our model's rMSE for a two-hour horizon for hold-out unseen patients was 29.81 mg/dL for type 1 diabetes and 23.49 mg/dL for type 2 diabetes for WellDoc data, and 26.30 mg/dL for the OhioT1DM data. The superior performance of CGM-LSM enables patients and healthcare providers to make timely and precise interventions, potentially reducing patients' risk for hypoglycemia and hyperglycemia episodes. For both T1D and T2D patients, CGM-LSM's accuracy can support improved daily glucose management, potentially reducing the incidence of more severe complications. These advances could ultimately lead to better health outcomes, lower healthcare costs, empowered self-management, and enhancement in the quality of life.

In addition to accuracy, robustness is critical for evaluating prediction performance, requiring reliable performance for both unseen future periods and new patients. To examine CGM-LSM's robustness, we implemented a dual-dimension evaluation strategy with a "temporal" test set for unseen future periods and a "hold-out" test set for unseen new patients. Our model exhibited consistent prediction performance for all evaluation sets. The performance gap between the temporal and hold-out sets versus the internal set remained small, indicating that our model can effectively perform prediction tasks involving unseen future periods or unseen patients. It is noteworthy that many prior glucose prediction studies either omitted these evaluations or the model's performance deteriorated when applied to unseen patients, raising questions about its robustness and broader applicability¹⁴. Our second robustness evaluation examined performance across diabetes type, age, and gender. CGM-LSM maintained stable prediction performance across demographic groups and identified certain groups that require customized model adjustments for better prediction performance. For diabetes type, the model's performance for T1D is close to that for T2D, with T2D showing better results. This notably better performance is intriguing, as it suggests that T1D may present a more complex prediction challenge requiring further study. We also note that our model showed higher accuracy and robustness for older patients, male patients, and T2D patients than for younger, female and T1D patients. Overall, however, our results demonstrated significant improvements in prediction across all groups, indicating equitable and reliable performance. Our third robustness test examined prediction performance across different times of day and found that at all times, our model consistently outperformed the baseline model. We observed different accuracy across hours, with higher rMSE in the late afternoon/evening and lower rMSE late at night. This fluctuation in model performance reveals how human behaviors influence the performance of LSM and highlights the potential of incorporating human behaviors into foundation models for even more accurate glucose predictions.

The robustness of our model for future, unseen, and diverse patients has significant clinical implications. It enables immediate personalized care and timely interventions. Drawing on limited patient history, our model provides reliable predictions for clinical decision support and broader

use. This reliability builds trust and facilitates preventive care. CGM-LSM's superior prediction accuracy and robustness is driven by its pretraining on the massive CGM data, which allows the model to understand the human behavior information and glucose generation mechanisms from sensor curves. Through five-minute glucose predictions, CGM-LSM distills knowledge from the glucose curves that develop temporally from the interaction between human behaviors and biological mechanisms. Its success indicates the value of applying foundation models to large sensor data for improved prediction. Remarkably, CGM-LSM achieves accurate predictions even without detailed activity data, indicating that it captures activities and their effects using the curve's fluctuations. Given the challenges of collecting behavioral data, achieving accurate predictions using only glucose data represents significant progress.

Our study has several key limitations. First, we did not include activity data (medication, diet, exercise, education) or laboratory measurements, which could potentially improve model performance. Second, the model's robustness was only assessed across age and gender, excluding critical demographic aspects like race, ethnicity, and socioeconomic status. Third, the lack of patient-specific fine-tuning in the CGM-LSM model limits its applicability and personalization. Lastly, once patients adjust their behavior based on the prediction, it is not clear whether CGM-LSM will continue to perform well. Extra investigations in pretraining and fine-tuning are needed for these problems.

In conclusion, this paper is the first to utilize sensor data, specifically CGM data, to pretrain a large sensor model. This innovative approach demonstrates the potential of integrating sensor data and advanced AI techniques, setting a foundation for future research in this area. The superior performance of CGM-LSM demonstrates the feasibility of introducing foundation models from texts, images, and videos to human sensor records. Such data is becoming increasingly massive and ubiquitous given the widespread adoption of wearable devices²¹. With these data, various LSMs could be developed to advance the understanding and management to other diseases, like uncovering new knowledge about body mechanisms from heart rate, blood pressure, body temperature, weight, respiratory rate, and oxygen saturation. These LSMs could enable significant improvement in human health prediction, not only in accuracy, but also in robustness, customization, and granularity.

References

1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. *Cardiovasc Diabetol*. 2018;17(1):83. doi:10.1186/s12933-018-0728-6
2. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. *J Clin Invest*. 2014;124(6):2333-2340. doi:10.1172/JCI72271
3. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care*. 2017;40(1):136-154. doi:10.2337/dc16-2042
4. Parker ED, Lin J, Mahoney T, et al. Economic Costs of Diabetes in the U.S. in 2022. *Diabetes Care*. 2024;47(1):26-43. doi:10.2337/dci23-0085
5. Dall T, West T, Ritashree Chakrabarti, Reynolds R, Iacobucci W. 2018 Update The Complexities of Physician Supply and Demand: Projections from 2016 to 2030 Final Report Association of American Medical Colleges. Published online 2018. doi:10.13140/RG.2.2.25694.48963
6. Sheng B, Guan Z, Lim LL, et al. Large language models for diabetes care: Potentials and prospects. *Science Bulletin*. 2024;69(5):583-588. doi:10.1016/j.scib.2024.01.004
7. Kolb L. An Effective Model of Diabetes Care and Education: The ADCES7 Self-Care Behaviors™. *The Science of Diabetes Self-Management and Care*. 2021;47(1):30-53. doi:10.1177/0145721720978154
8. Midyett LK. One Size Fits All Versus Individualized Medicine in Type 1 Diabetes Management. *Diabetes Technology & Therapeutics*. 2023;25(S3):S-42. doi:10.1089/dia.2023.0109
9. Vettoretti M, Cappon G, Facchinetti A, Sparacino G. Advanced Diabetes Management Using Artificial Intelligence and Continuous Glucose Monitoring Sensors. *Sensors (Basel)*. 2020;20(14):3870. doi:10.3390/s20143870
10. Doorn WPTM van, Foreman YD, Schaper NC, et al. Machine learning-based glucose prediction with use of continuous glucose and physical activity monitoring data: The Maastricht Study. *PLOS ONE*. 2021;16(6):e0253125. doi:10.1371/journal.pone.0253125
11. Zecchin C, Facchinetti A, Sparacino G, De Nicolao G, Cobelli C. Neural Network Incorporating Meal Information Improves Accuracy of Short-Time Prediction of Glucose Concentration. *IEEE Transactions on Biomedical Engineering*. 2012;59(6):1550-1560. doi:10.1109/TBME.2012.2188893
12. Li K, Daniels J, Liu C, Herrero P, Georgiou P. Convolutional Recurrent Neural Networks for Glucose Prediction. *IEEE Journal of Biomedical and Health Informatics*. 2020;24(2):603-613. doi:10.1109/JBHI.2019.2908488

13. Li K, Liu C, Zhu T, Herrero P, Georgiou P. GluNet: A Deep Learning Framework for Accurate Glucose Forecasting. *IEEE Journal of Biomedical and Health Informatics*. 2020;24(2):414-423. doi:10.1109/JBHI.2019.2931842
14. Zhu T, Li K, Herrero P, Georgiou P. Personalized Blood Glucose Prediction for Type 1 Diabetes Using Evidential Deep Learning and Meta-Learning. *IEEE Transactions on Biomedical Engineering*. 2023;70(1):193-204. doi:10.1109/TBME.2022.3187703
15. Deng Y, Lu L, Aponte L, et al. Deep transfer learning and data augmentation improve glucose levels prediction in type 2 diabetes patients. *npj Digit Med*. 2021;4(1):1-13. doi:10.1038/s41746-021-00480-x
16. Zhu T, Chen T, Kuang L, Zeng J, Li K, Georgiou P. Edge-Based Temporal Fusion Transformer for Multi-Horizon Blood Glucose Prediction. In: *2023 IEEE International Symposium on Circuits and Systems (ISCAS)*. ; 2023:1-5. doi:10.1109/ISCAS46773.2023.10181448
17. Marling C, Bunescu R. The OhioT1DM Dataset for Blood Glucose Level Prediction: Update 2020. *CEUR Workshop Proc*. 2020;2675:71-74.
18. Radford A, Wu J, Child R, Luan D, Amodei D, Sutskever I. Language Models are Unsupervised Multitask Learners.
19. Kalyani RR, Egan JM. Diabetes and Altered Glucose Metabolism with Aging. *Endocrinology and Metabolism Clinics*. 2013;42(2):333-347. doi:10.1016/j.ecl.2013.02.010
20. Tramunt B, Smati S, Grandgeorge N, et al. Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia*. 2020;63(3):453-461. doi:10.1007/s00125-019-05040-3
21. Dunn J, Runge R, Snyder M. Wearables and the medical revolution. *Per Med*. 2018;15(5):429-448. doi:10.2217/pme-2018-0044
22. Ashish V. Attention is All you Need. *Advances in Neural Information Processing Systems*. 2017;30:I.
23. Brown T, Mann B, Ryder N, et al. Language Models are Few-Shot Learners. In: *Advances in Neural Information Processing Systems*. Vol 33. Curran Associates, Inc.; 2020:1877-1901. Accessed July 19, 2024. <https://proceedings.neurips.cc/paper/2020/hash/1457c0d6bfcb4967418bfb8ac142f64a-Abstract.html>
24. Hochreiter S, Schmidhuber J. Long Short-Term Memory. *Neural Computation*. 1997;9(8):1735-1780. doi:10.1162/neco.1997.9.8.1735
25. Wolf T, Debut L, Sanh V, et al. Transformers: State-of-the-Art Natural Language Processing. In: Liu Q, Schlangen D, eds. *Proceedings of the 2020 Conference on Empirical Methods in Natural Language Processing: System Demonstrations*. Association for Computational Linguistics; 2020:38-45. doi:10.18653/v1/2020.emnlp-demos.6
26. Loshchilov I, Hutter F. Decoupled Weight Decay Regularization. Published online January 4, 2019. Accessed July 19, 2024. <http://arxiv.org/abs/1711.05101>

27. Wiher G, Meister C, Cotterell R. On Decoding Strategies for Neural Text Generators. *Transactions of the Association for Computational Linguistics*. 2022;10:997-1012. doi:10.1162/tacl_a_00502
28. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019;42(8):1593-1603. doi:10.2337/dci19-0028

Supplementary Appendix

This appendix accompanies ***Let Curves Speak: A Continuous Glucose Monitor Based Large Sensor Foundation Model for Diabetes Management*** and been provided by the authors to give readers additional information about this paper.

Junjie Luo, M.S.,^{1,2} Abhimanyu Kumbara, M.S.,³ Mansur Shomali, M.D.,³ Rui Han, M.S.,^{2,4} Anand Iyer, Ph.D., M.B.A.,³ Ritu Agarwal, Ph.D., M.B.A.,^{2,4} Gordon Gao, Ph.D., M.B.A.,^{2,4}

¹ School of Medicine, Johns Hopkins Univeristy

² The Center for Digital Health and Artificial Intelligence

³ WellDoc Inc.

⁴ Carey Business School, Johns Hopkins University

Table of Contents

1. Additional Details	17
1.1 Datasets	17
1.2 Training and evaluation datasets	19
1.3 Problem definition for pretraining	20
1.4 Problem definition for prediction/generation	21
1.5 CGM-LSM model structure	22
1.6 CGM-LSM implementation details	24
1.7 Model evaluation	25
2. Supplementary Figures and Tables	27
2.1 Extended Data: Figure1 Data Collection for WellDoc Dataset	27
2.2 Extended Data: Figure1 Data Collection for OhioT1DM Dataset	28
2.3 Extended Data: Model Results with rMSE	29
2.4 Extended Data: Model Results with MAE	30
2.5 Extended Data: Model Results with MAE_Tol10	31
2.6 Extended Data: Model Results with Region-Accuracy (RegionAccu)	32
2.7 Extended Data: Figure – Performance Across Age	33
2.8 Extended Data: Figure – Performance Across Gender	34
2.9 Extended Data: Figure – Performance Across Prediction-Making Hours of the Day	35
2.10 Extended Data: Model Prediction Examples	36
References	37

1. Additional Details

1.1 Datasets

The protocol was approved by the Johns Hopkins School of Medicine institutional review board (IRB00447704). For this study, we used two datasets for our analysis: CGM data collected from Welldoc, Inc. for pretraining and the OhioT1DM data for benchmarking.

WellDoc Data: This dataset, used for pretraining the CGM-LSM model, initially contained 21,215,912 CGM records from 617 patients. The data were de-identified, with only **patients'** age, gender, and diabetes type available for analysis.

We constructed instances to align with the context where for a given patient and an instance datetime, the model predicted future health outcomes based on available patient information. Thus, each instance was associated with a patient and a specific instance datetime. Instance datetimes were derived from the entry times recorded in the CGM system. In the application scenarios, when new glucose data are recorded from the CGM system, our model is triggered to observe patient information and then predict glucose levels for the next two hours.

To ensure that each instance had sufficient glucose readings for effective learning by the model, we applied specific filtration criteria to retain only valid instances from the raw dataset. First, we assessed the adequacy of input data based on the number of CGM records available prior to the instance datetime. Specifically, we required that a patient have 288 CGM readings recorded in the 24 hours preceding the instance datetime to be included. Additionally, to mitigate the influence of consistent measurement errors that might skew the data, we calculated the mode rate of the CGM sequence. Any instance with a mode rate exceeding 40% was excluded to avoid potential noise in the dataset.

Second, for an instance to be considered valid, we imposed the restriction that it contains reliable “output” data for prediction. This required the data to include a complete record of the subsequent two hours of CGM data (24 CGM records) following the instance datetime. We imposed the requirement of a mode rate below 40% for these two-hour CGM records as well.

We chose a 24-hour window prior to the instance datetime to encapsulate daily patterns and provide a comprehensive view of a patient’s typical day. The subsequent two-hour window was selected because it is deemed clinically significant. Compared to shorter spans such as 30 minutes or one hour, a two-hour prediction window offers a balance of enabling accurate short-term forecasts and avoiding the increased uncertainty associated with longer prediction horizons, such as three hours, which may introduce unreliability due to numerous unobserved variables.

After filtering the data as described above, we **retained** 15,961,183 valid CGM records from 592 individuals. Of these patients, 291 have type 1 diabetes (T1D) and 301 have type 2 diabetes (T2D). The participants are 52.2% male (309 individuals) and 47.8% female (283 individuals). The dataset includes time-stamped glucose records that were utilized for model training. Compared with

previous benchmark data, our novel Welldoc dataset is substantially larger, with CGM data from **diverse** patient types.

OhioT1DM Data: The OhioT1DM CGM dataset¹ is a publicly available collection of continuous glucose monitoring (CGM) data from patients with type 1 diabetes. The dataset was divided into a training and a test set. For comparison with baseline models from previous studies, we focused on the test dataset, which included 15,970 CGM records from 6 patients with time-stamped glucose values. After applying the inclusion criteria used for Welldoc data, we retained 5,802 valid instances from 5 patients. This dataset did not include patient demographic information.

1.2 Training and evaluation datasets

To ensure robust evaluation of model performance in terms of accuracy and robustness, we adopted a stringent methodology for splitting data. For the Welldoc dataset, patients were divided into a hold-in group and a hold-out group. The hold-out test set, comprising 10% of the patients, was excluded from the training process and reserved exclusively for evaluation. We also used the OhioT1DM data as a second hold-out test set.

The hold-in group, which included 90% of the patients, was processed further. We ordered each patient's CGM recorded glucose values chronologically by instance datetime. The last 10% of these instances were designated as the "temporal" test set, reserved for temporal validation. The remaining 90% of instances were randomly divided, with 10% forming the "internal" test set and 80% designated for training. This approach allowed the model to be tested against both time periods as well as against patients it had not previously encountered, thereby enhancing the evaluation of its predictive capabilities.

To prevent overfitting and to improve computational efficiency, we applied a random 10% down-sampling strategy to each dataset. This down-sampling was strategically chosen based on the proximity of instance datetimes within instances. Closely timed instances often have substantial overlap in their CGM inputs and outputs, potentially skewing the model's learning with redundant information. For example, if a patient had two instances with instance datetimes of 11:00 am and 11:30 am on the same day, their CGM input data and CGM output data would overlap substantially. This down-sampling thus ensured a sparser distribution of instance times, optimizing training efficiency. All random splits were performed using a fixed random seed of 42 to ensure reproducibility.

Additionally, since each instance was associated with a specific patient and datetime, we were able to subdivide the data further into more granular datasets based on available patient characteristics of age, gender, and diabetes type, and the temporal feature of time of day. To illustrate, using the hold-out set as an example, we generated specific test sets based on patient characteristics, such as "hold-out T1D," "hold-out T1D female," or "hold-out T1D 18-30 years old." Similarly, we created test sets based on datetime features, such as "hold-out T1D 2pm," which would include instances from T1D patients in the hold-out group with instance datetimes at 2pm.

1.3 Problem definition for pretraining

We represented a sequence of 312 CGM values with timestamps as $(s_1, s_2, s_3, \dots, s_n)$ for a 26-hour period (24 hours before the focal datetime and 2 hours after). This sequence has a natural sequential ordering, similar to natural language. Following the logic of a language model, the large sensor model is trained to predict the next glucose value given a CGM sensor data sequence using the autoregression method.

Mathematically, this can be described as maximizing the likelihood of a glucose value s_i given the preceding glucose values s_1, \dots, s_{i-1} . The objective function for training the CGM-LSM model is formalized as follows:

$$L(\theta) = \sum_{i=1}^n \log p_{\theta}(s_i | s_1, \dots, s_{i-1})$$

where θ represents the parameters of the model, n is the length of the input sequence, and $p_{\theta}(s_i | s_1, \dots, s_{i-1})$ is the probability of the glucose value s_i conditioned on the prior sequence of tokens, as computed by the model. This training paradigm encourages the development of internal representations that capture glucose generation mechanism dependencies between elements in the input sequence, enabling the model to generate coherent and contextually relevant glucose values in future glucose prediction tasks. By repeatedly adjusting θ to maximize $L(\theta)$, the CGM-LSM model learns to anticipate subsequent glucose value effectively. In our CGM-LSM model, we adopted the popular transformer decoder-only structure to model the above task, and we conduct our pre-training task based on the CGM data.

1.4 Problem definition for prediction/generation

After the CGM-LSM was trained, it could be used to generate new glucose sequences. The generation process of CGM-LSM is similar to that of the GPT models. It involves iteratively sampling a new generated glucose value (token) from a probability distribution of possible next glucose values (tokens), conditioned on a sequence of input glucose values (tokens). This is mathematically represented as:

$$p(s_{i+1}|s_1, \dots, s_i; \theta) = \text{softmax}(h_i W)$$

where θ denotes the model parameters, h_i is the hidden state derived from transformer blocks, and W is the output projection matrix. The generation starts with an initial sequence, i.e., the preceding 24-hour CGM data sequence. Each timestep's hidden glucose state is computed and used to generate a probability distribution over the vocabulary from which the glucose value in the next time stamp is sampled. This can be done using random sampling or techniques like top-k or top-p sampling to balance creativity and coherence. For our application, we used the greedy method, which samples the glucose value with the highest probability. This predicted glucose value is then treated as the real value and appended to the original sequence for the next glucose value prediction. The process repeats until the maximum length, i.e., 24 glucose values for the next two hours, is reached. Finally, the generated 2-hour glucose values are compared with the real glucose values to measure the model's prediction performance.

1.5 CGM-LSM model structure

Input Representation. The tokens used in CGM-LSM for glucose prediction were the glucose values themselves. Various methods exist for converting numerical values into categorical tokens. For simplicity and without losing generality, we directly used the glucose readings as tokens; for instance, a glucose level of 153 becomes the token “153.” In total, we had 400 glucose value tokens in the vocabulary because the maximum value of glucose measured by the CGM device is 400. In the pretraining tasks involving next glucose value prediction, the model was expected to learn the semantic meanings of the embeddings for these glucose value tokens.

Model Structure. CGM-LSM adopted the transformer decoder-only structure², which is widely used in GPT model series^{3,4}. In contrast to traditional recurrent neural networks⁵, this approach relies entirely on self-attention mechanisms to generate sequences. Such an architecture facilitates more parallelizable computations and effectively captures long-range dependencies in data.

In a decoder-only transformer, the model is composed exclusively of a stack of decoder blocks that process the input sequence to generate one glucose value token at a time. Each decoder block in the transformer comprises two main components: a multi-head self-attention mechanism and a position-wise fully connected feed-forward network.

The input to each decoder layer is initially transformed into three vectors—query (Q), key (K), and value (V) vectors—through linear projection of the embeddings of the input tokens. The self-attention mechanism in the decoder is mathematically represented as:

$$\text{Attention}(Q, K, V) = \text{softmax}\left(\frac{QK^T}{\sqrt{d_k}}\right)V,$$

where d_k is the dimension of the key vectors. This mechanism allows each position in the decoder to attend to all positions up to and including that position in the previous layer. This is crucial for autoregressive models where the prediction for the next token can only depend on the known previous tokens, thereby preserving the causality in the sequence generation.

Normalization and residual connections are employed around each of these sublayers (self-attention and feed-forward networks), which help in stabilizing the learning process. Mathematically, the output of each sublayer can be described as:

$$\text{LayerNorm}(x + \text{Sublayer}(x)),$$

where $\text{Sublayer}(x)$ is the function implemented by the sublayer itself, either self-attention or a feed-forward network, and x is the input to the sublayer.

Finally, after passing through the series of decoder blocks, the output is projected onto a vocabulary-sized vector using a linear transformation followed by a softmax layer to produce a probability distribution over possible next tokens:

$$p(s_{i+1}|s_1, \dots, s_i) = \text{softmax}(h_i W),$$

where h_i is the final layer's output at position i and W is the weight matrix. The glucose value corresponding to the highest probability is then selected as the next token in the sequence. The decoder-only transformer architecture leverages the power of self-attention to efficiently process sequences in a manner that scales favorably with sequence length and allows for highly parallelizable implementation.

Loss Function. Because we treated a glucose value as a unique token, we used cross-entropy to calculate the loss for the next glucose value prediction task. In the pretraining of the CGM-LSM model, the softmax function is instrumental in transforming the logits—raw output scores for each glucose value in the vocabulary—into a probability distribution over all potential next glucose values. This probabilistic framework is crucial for defining the cross-entropy loss, which quantifies the difference between the predicted probabilities and the actual distribution of the next glucose value. Specifically, given the logits \mathbf{z}_t , for possible next glucose values at position $t + 1$, the softmax function calculates the probability of each token x_t being the next token in the sequence as follows:

$$p_{\theta}(s_{t+1} | s_1, \dots, s_t) = \frac{\exp(z_{t,s_t})}{\sum_{k=1}^V \exp(z_{t,k})}$$

where V is the vocabulary size and $z_{t,k}$ represents the logit corresponding to the k -th vocabulary token. The cross-entropy loss for predicting a single token is thus:

$$\text{Loss} = -\log p_{\theta}(s_{t+1} | s_1, \dots, s_t)$$

This loss essentially measures the model's effectiveness in predicting the actual next token s_{t+1} using the probabilities output by the softmax function. By minimizing the negative log-likelihood, or equivalently, the cross-entropy loss across all tokens in the training dataset, the GPT model learns to generate accurate and coherent text. The total loss for a batch of sequences, which aggregates the individual token losses, ensures comprehensive learning across diverse textual contexts:

$$\text{Total Loss} = -\sum_{i=1}^N \sum_{t=1}^{T_i} \log \left(\frac{\exp(z_{i,t-1,s_{i,t}})}{\sum_{k=1}^V \exp(z_{i,t-1,k})} \right)$$

Through iterative minimization of this total loss during pretraining, the CGM-LSM model effectively hones its parameter set θ , thereby enhancing its capabilities in language modeling and next-token prediction.

1.6 CGM-LSM implementation details

We utilized the GPT-2 model, as implemented in the Hugging Face library⁶, as the foundation for CGM-LSM. The model's token vocabulary contained 17 special tokens and 400 glucose value tokens. For the CGM-LSM structure, the embedding size was 786, the number of multi-heads was 12, and the number of layers was 12.

For model training with the Welldoc training dataset, we set batch size to 256. For the optimizer, we used AdamW⁷ with β_1 to be 0.9 and β_2 to be 0.999. Grid search was used to obtain the optimal hyperparameters. We set the learning rate to be 0.00005, the layer norm epsilon value as 0.00001, and dropout rate as 0.1. We conducted the training process on a single A100 80GB GPU over ten epochs. Notably, towards the end of the third epoch, we observed an increment in loss on the validation sets. We therefore used the model instance at the end of the third epoch as our final model.

Post-training, the model's capability to generate new sequences was tested using Hugging Face's generation functions on the same type of GPU. We employed the greedy sampling method⁸ to predict glucose values over a two-hour horizon, terminating after the 24th token. After that, we calculated evaluation metrics for the model's prediction performance by comparing these predicted glucose sequences against actual glucose data.

1.7 Model evaluation

In this study, we evaluated model performance using four metrics: root Mean Squared Error (rMSE), Mean Absolute Error (MAE), MAE with a tolerance of 10 units (MAEWith10), and Region Accuracy. These metrics capture the precision and reliability of predictive models in continuous glucose monitoring (CGM) and have been widely used in previous studies of CGM glucose prediction^{9,10}.

Root Mean Squared Error (rMSE) is a robust metric used to quantify the average magnitude of the error between predicted values and actual values. It is computed using the formula:

$$\text{RMSE} = \sqrt{\frac{1}{n} \sum_{i=1}^n (y_i - \hat{y}_i)^2}$$

where y_i are the actual values, \hat{y}_i are the predicted values, and n is the number of instances.

Mean Absolute Error (MAE) measures the average magnitude of the errors in prediction without considering their direction. It is simpler and particularly useful when you need to understand errors in the same units as the data. MAE is calculated as:

$$\text{MAE} = \frac{1}{n} \sum_{i=1}^n |y_i - \hat{y}_i|$$

MAE with Tolerance (MAE(τ)), an adaptation of the traditional MAE, measures the proportion of absolute errors that fall within a specified tolerance level, here set at 10 units. This metric is particularly useful in applications where errors within a certain range are considered acceptable. The calculation is:

$$\text{MAE}(\tau) = \frac{1}{n} \sum_{i=1}^n \min(\max(0, |y_i - \hat{y}_i| - \tau), 1)$$

Glucose Region Accuracy evaluates the accuracy of predictions by categorizing continuous glucose values into predefined regions and comparing these categorical predictions to actual categorizations. The regions are defined as Very Low (<54 mg/dL), Low (54-69 mg/dL), Time-in-Range (TIR) (70-180 mg/dL), High (181-250 mg/dL), and Very High (>250 mg/dL)¹¹. The accuracy is then calculated by:

$$\text{Accuracy} = \frac{\text{Number of correct predictions}}{\text{Total number of predictions}}$$

Collectively, these metrics offered us a comprehensive view of the model's performance, each adding a unique dimension to our understanding of model accuracy and reliability in prediction of glucose levels. The use of varied metrics ensured a balanced evaluation that addressed both the magnitude of errors and their clinical significance.

2. Supplementary Figures and Tables

2.1 Figure S1: Data Construction for the WellDoc Dataset




Figure S1: Data Construction for the WellDoc Dataset.

2.2 Figure S2: Data Construction for the OhioT1DM Dataset




Figure S2: Data Construction for the OhioT1DM Dataset.

2.3 Table S1: Model Results with rMSE

Diabetes Type	Evaluation Set	rMSE-30Min	rMSE-1stH	rMSE-2H
Type 1 Diabetes	OhioT1DM	9.358 (0.684)	15.64 (1.078)	26.296 (1.664)
Type 1 Diabetes	Internal Test	8.403 (0.066)	16.049 (0.118)	28.277 (0.188)
	Temporal Test	9.155 (0.068)	17.013 (0.118)	29.426 (0.184)
	Hold-Out Test	8.926 (0.056)	16.905 (0.101)	29.812 (0.16)
Type 2 Diabetes	Internal Test	7.441 (0.055)	13.418 (0.094)	22.649 (0.147)
	Temporal Test	8.025 (0.058)	14.073 (0.095)	23.216 (0.143)
	Hold-Out Test	7.772 (0.055)	13.877 (0.091)	23.494 (0.143)

Table S1: Model Results with rMSE

2.4 Table S2: Model Results with MAE

Diabetes Type	Evaluation Set	MAE-30Min	MAE-1stH	MAE-2H
Type 1 Diabetes	OhioT1DM	8.119 (0.608)	13.408 (0.957)	22.178 (1.449)
Type 1 Diabetes	Internal Test	7.001 (0.056)	13.295 (0.099)	23.461 (0.16)
	Future Test	7.691 (0.058)	14.205 (0.101)	24.552 (0.158)
	Hold-Out Test	7.497 (0.048)	14.099 (0.085)	24.889 (0.138)
Type 2 Diabetes	Internal Test	6.246 (0.047)	11.19 (0.08)	18.876 (0.125)
	Temporal Test	6.805 (0.05)	11.833 (0.081)	19.472 (0.123)
	Hold-Out Test	6.571 (0.047)	11.64 (0.078)	19.678 (0.123)

Table S2: Model Results with MAE

2.5 Table S3: Model Results with MAE (10)

Diabetes Type	Evaluation Set	MAE(10)-30Min	MAE(10)-1stH	MAE(10)-2H
Type 1 Diabetes	OhioT1DM	0.747 (0.024)	0.587 (0.026)	0.42 (0.022)
Type 1 Diabetes	Internal Test	0.7921 (0.0021)	0.6132 (0.0024)	0.4383 (0.0022)
	Future Test	0.7681 (0.0021)	0.5912 (0.0023)	0.4229 (0.0021)
	Hold-Out Test	0.7717 (0.0018)	0.5879 (0.002)	0.4125 (0.0018)
Type 2 Diabetes	Internal Test	0.8179 (0.002)	0.6578 (0.0023)	0.4927 (0.0022)
	Temporal Test	0.7986 (0.002)	0.6405 (0.0023)	0.4803 (0.0022)
	Hold-Out Test	0.8074 (0.0019)	0.6463 (0.0022)	0.4801 (0.0021)


Table S3: Model Results with MAE(10)

2.6 Table S4: Model Results with Region-Accuracy


Diabetes Type	Evaluation Set	RegionAccu-30Min	RegionAccu-1stH	RegionAccu-2H
Type 1 Diabetes	OhioT1DM	0.902 (0.018)	0.842 (0.021)	0.763 (0.024)
Type 1 Diabetes	Internal Test	0.9352 (0.0014)	0.8803 (0.0018)	0.8016 (0.0021)
	Temporal Test	0.9283 (0.0014)	0.8724 (0.0017)	0.7932 (0.0021)
	Hold-Out Test	0.925 (0.0012)	0.8649 (0.0016)	0.7785 (0.0018)
Type 2 Diabetes	Internal Test	0.9475 (0.0012)	0.9054 (0.0016)	0.8457 (0.0019)
	Temporal Test	0.9435 (0.0012)	0.9017 (0.0015)	0.8431 (0.0018)
	Hold-Out Test	0.9414 (0.0012)	0.8964 (0.0015)	0.8327 (0.0018)

Table S4: Model Results with Region-Accuracy

2.7 Figure S3: – Performance Across Age for Different Prediction Horizons



a. Model performance across age groups for 30-minute prediction horizon



b. Model performance across age groups for one-hour prediction horizon.

Figure S3: CGMLSM’s prediction performance in different prediction horizons across age groups. (a) rMSE-1Hour prediction performance across age groups. (b) rMSE-30Min performance across age groups.

2.8 Figure S4: Performance Across Gender for Different Prediction Horizons

TODO





Figure S4: CGMLSM's prediction performances in different prediction horizons across gender groups. (a) rMSE-1Hour prediction performance across gender groups. (b) rMSE-30Min performance across gender groups.

2.9 Figure S5: Performance Across Prediction-Making Hours of the Day on Evaluation Sets.

A. Model performance across hour of the day in the concurrent (validation) evaluation set



B. Model performance across hour of the day in the future (temporal) evaluation set




Figure S5: Examples of good, moderate, and bad predictions made by the model.

2.10 Figure S6: Model Prediction Examples




Figure S6: Examples of good, moderate, and bad predictions made by the model.

References

1. Marling C, Bunescu R. The OhioT1DM Dataset for Blood Glucose Level Prediction: Update 2020. *CEUR Workshop Proc.* 2020;2675:71-74.
2. Ashish V. Attention is All you Need. *Advances in Neural Information Processing Systems*. 2017;30:l.
3. Radford A, Wu J, Child R, Luan D, Amodei D, Sutskever I. Language Models are Unsupervised Multitask Learners.
4. Brown T, Mann B, Ryder N, et al. Language Models are Few-Shot Learners. In: *Advances in Neural Information Processing Systems*. Vol 33. Curran Associates, Inc.; 2020:1877-1901. Accessed July 19, 2024. <https://proceedings.neurips.cc/paper/2020/hash/1457c0d6bfcb4967418bfb8ac142f64a-Abstract.html>
5. Hochreiter S, Schmidhuber J. Long Short-Term Memory. *Neural Computation*. 1997;9(8):1735-1780. doi:10.1162/neco.1997.9.8.1735
6. Wolf T, Debut L, Sanh V, et al. Transformers: State-of-the-Art Natural Language Processing. In: Liu Q, Schlangen D, eds. *Proceedings of the 2020 Conference on Empirical Methods in Natural Language Processing: System Demonstrations*. Association for Computational Linguistics; 2020:38-45. doi:10.18653/v1/2020.emnlp-demos.6
7. Loshchilov I, Hutter F. Decoupled Weight Decay Regularization. Published online January 4, 2019. Accessed July 19, 2024. <http://arxiv.org/abs/1711.05101>
8. Wiher G, Meister C, Cotterell R. On Decoding Strategies for Neural Text Generators. *Transactions of the Association for Computational Linguistics*. 2022;10:997-1012. doi:10.1162/tacl_a_00502
9. Doorn WPTM van, Foreman YD, Schaper NC, et al. Machine learning-based glucose prediction with use of continuous glucose and physical activity monitoring data: The Maastricht Study. *PLOS ONE*. 2021;16(6):e0253125. doi:10.1371/journal.pone.0253125
10. Zhu T, Chen T, Kuang L, Zeng J, Li K, Georgiou P. Edge-Based Temporal Fusion Transformer for Multi-Horizon Blood Glucose Prediction. In: *2023 IEEE International Symposium on Circuits and Systems (ISCAS)*. ; 2023:1-5. doi:10.1109/ISCAS46773.2023.10181448
11. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019;42(8):1593-1603. doi:10.2337/dci19-0028